ABBOTT INDIA LTD. - 500488 - Clarification sought from Abbott India Ltd
The Exchange has sought clarification from Abbott India Ltd on March 30, 2020, with reference to news appeared in moneycontrol.com dated March 28, 2020 quoting "Abbott gets approval to launch 5-minute COVID-19 test for use almost anywhere" The reply is awaited. 20 stocks hit 52-week highs on NSE
Among the stocks that touched their 52-week highs were Abbott India and Sanofi India.
Abbott launches quadrivalent vaccine for influenza in India
"We are excited with the launch of the quadrivalent version of our flu vaccine, which can be offered to both children above six months and adults. This particular type of vaccine provides good immune response with less side-effects," Abbott India Medical Director Srirupa Das said. ABBOTT INDIA LTD. - 500488 - Announcement under Regulation 30 (LODR)-Change in Directorate
1. Mr Jawed Zia (DIN: 00191276) has resigned from the Board of the Company effective close of business hours on February 29, 2020. This is consequent to his resignation from the services of Abbott due to personal reasons. 2. Mr Ambati Venu (DIN: 07614849) will be taking up a new role as Vice President, Established Pharmaceutical Products, within the Abbott Group in India with effect from March 1, 2020 and has, therefore, resigned as Managing Director of the Company effective close of business hours on February 29, 2020. Further, the Board has, with a view to continue to leverage extensive experience held by Mr Ambati in the areas of pharmaceuticals and his deep understanding and knowledge about the Company's operations, approved his appointment as Additional Director (Non-Executive, Non-Independent), with effect from March 1, 2020, subject to approval of shareholders at the forthcoming Annual General Meeting. Abbott India Ltd - 500488 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Abbott India Limited has informed BSE regarding Loss of Share Certificate / Issue of Duplicate Share Certificate.
Buy Abbott India target of Rs 16880: ICICI Direct
rnICICI Direct is bullish on Abbott India has recommended buy rating on the stock with a target price of Rs 16880 in its research report dated February 10, 2019. ABBOTT INDIA LTD. - 500488 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the newspaper cuttings of the Unaudited Financial Results of the Company for the third quarter and nine months ended on December 31, 2019 published in Business Standard (All Editions) and Loksatta on Saturday February 8, 2020. This is for your information and record.
Abbott India Q3 net profit rises 59% to Rs 187cr
Its revenue from operations stood at Rs 1,078.25 crore for the quarter under consideration as against Rs 947.65 crore for the corresponding period a year ago. Abbott India Ltd - 500488 - Unaudited Financial Results For The Third Quarter And Nine Months Ended On December 31, 2019
Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose a text of Unaudited Financial Results of the Company for the third quarter and nine months ended on December 31, 2019, approved by the Board of Directors at its Meeting held on Friday, February 7, 2020 along with the Limited Review Report issued by S R B C & CO. LLP, Statutory Auditors of the Company. The Meeting of the Board of Directors of the Company commenced at 11.30 am and concluded at 2.00 pm. ABBOTT INDIA LTD. - 500488 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Abbott India Limited has informed BSE regarding Loss of Share Certificate / Issue of Duplicate Share Certificate.